Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology
- 2 February 2011
- journal article
- review article
- Published by Springer Nature in International Ophthalmology
- Vol. 31 (2) , 165-173
Abstract
Tumor necrosis factor alpha (TNF-α) is a key soluble mediator involved in the inflammatory cascade of many disorders including uveitis. Among the anti-TNF-α agents, one of the most used in immune-mediated diseases, such as inflammatory arthropathies, is adalimumab (Humira™, Abbott Pharmaceutical Inc.), a fully humanized antibody. The purpose of this review is to analyze the main pharmacological and clinical aspects of adalimumab and its efficacy both in systemic and ocular inflammatory disorders. Adalimumab was effective in treating several autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. In recent years, adalimumab has been used successfully in refractory cases of intraocular inflammation. Moreover, this biological agent showed good safety and efficacy profiles in ocular use including childhood uveitis. Switching from other anti-TNF-α agents to adalimumab may offer several advantages, such as easier administration, better patient compliance, and lower rate of adverse events. Adalimumab is a promising drug for the therapy of uveitis, although further studies are needed on its application in uveitis.Keywords
This publication has 51 references indexed in Scilit:
- Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesionsAnnals of the Rheumatic Diseases, 2010
- Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label studyAnnals of the Rheumatic Diseases, 2009
- Switching between anti-tumour necrosis factors: trying to get a handle on a complex issueAnnals of the Rheumatic Diseases, 2007
- Mycophenolate mofetil in the treatment of uveitis in childrenBritish Journal of Ophthalmology, 2007
- Adalimumab in the therapy of uveitis in childhoodBritish Journal of Ophthalmology, 2006
- Successful treatment of juvenile-onset HLA-B27-associated severe and refractory heel Thesitis with adalimumab documented by magnetic resonance imagingRheumatology, 2006
- Adalimumab for sight-threatening uveitis in Behçet's diseaseEye, 2006
- TNF-R1 Signaling: A Beautiful PathwayScience, 2002
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- ROLE OF CYTOKINES IN RHEUMATOID ARTHRITISAnnual Review of Immunology, 1996